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Abstract
Background: MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that regulate gene expression at
post-transcriptional level. The recent discovery of the involvement of these RNAs in the control of angiogenesis renders
them very attractive in the development of new approaches for restoring the angiogenic balance. Whereas miRNA-21 has
been demonstrated to be highly expressed in endothelial cells, the potential function of this miRNA in angiogenesis has
never been investigated.
Methodology/Principal Findings: We first observed in endothelial cells a negative regulation of miR-21 expression by
serum and bFGF, two pro-angiogenic factors. Then using in vitro angiogenic assays, we observed that miR-21 acts as a
negative modulator of angiogenesis. miR-21 overexpression reduced endothelial cell proliferation, migration and the ability
of these cells to form tubes whereas miR-21 inhibition using a LNA-anti-miR led to opposite effects. Expression of miR-21 in
endothelial cells also led to a reduction in the organization of actin into stress fibers, which may explain the decrease in cell
migration. Further mechanistic studies showed that miR-21 targets RhoB, as revealed by a decrease in RhoB expression and
activity in miR-21 overexpressing cells. RhoB silencing impairs endothelial cell migration and tubulogenesis, thus providing
a possible mechanism for miR-21 to inhibit angiogenesis. Finally, the therapeutic potential of miR-21 as an angiogenesis
inhibitor was demonstrated in vivo in a mouse model of choroidal neovascularization.
Conclusions/Significance: Our results identify miR-21 as a new angiogenesis inhibitor and suggest that inhibition of cell
migration and tubulogenesis is mediated through repression of RhoB.
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Introduction
Over the past few decades, microRNAs (miRNAs) have
emerged as a prominent class of gene regulators. miRNAs are
endogenous small single-strand non-coding RNAs of about 22
nucleotides [1]. Together with a protein complex known as RNA-
induced silencing complex (RISC), miRNA functions as a guide
molecule in post-transcriptional gene silencing by partially
complementing to the 39 untranslated region (UTR) of target
mRNA. Base-pairing between miRNA and mRNA leads to
translational repression or mRNA degradation [2]. To date, about
1000 miRNAs have been identified in humans. Each miRNA can
regulate up to hundreds of targets and miRNAs are predicted to
regulate a third of protein coding genes [3]. By regulating
numerous mRNAs, miRNAs play a key role in a wide range of
physiological and pathological processes [4,5].
Accumulating evidence indicates that aberrant miRNA expres-
sion profiles are observed in a variety of cancers. Among the many
miRNAs already identified as regulators of neoplastic transforma-
tion, invasion and metastasis, miR-21 has emerged as a key
miRNA dysregulated in many cancers [6]. miR-21 has been
reported to be highly expressed in breast [7], lung [8], pancreas
[9], prostate [10], stomach [10] and brain [11] cancers. An
increased expression of miR-21 in tumor cells is associated with a
higher proliferation and invasion capacity of these cells [12].
Moreover, elevated miR-21 expression in cancer has been shown
to be generally associated with poor prognosis [13].
Despite the numerous studies performed regarding the role of
miR-21 in tumor cells, its functions in endothelial cells remain to
be defined. Indeed, de novo angiogenesis is a critical factor in cancer
progression. Several specific miRNAs control blood vessel
formation, such as miR-126 [14]. This endothelial specific miRNA
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16979promotes blood vessel development by targeting negative
regulators of MAP kinase and PI3K signaling pathways [15,16].
miRNAs, regulating key angiogenic processes, are defined as
angiomiRs and to date, only a few angiomiRs have been described
[17]. Of these angiomiRs, some negatively regulate angiogenesis.
For example, miR-221 and miR-222 have been shown to block
angiogenesis due to their regulatory effect on the stem cell factor
receptor c-Kit [18]. In addition, the miR-17-92 cluster has also
been identified as a negative regulator of angiogenesis. In this
cluster, miR-92a inhibits angiogenesis both in vitro and in vivo [19].
More recently, miR-17/20 was shown to exert cell intrinsic
antiangiogenic activity [20].
Aberrant angiogenesis leads to a variety of pathologies such as
cancer, ischemia, psoriasis and age-related macular degeneration.
The angiogenesis status is defined by a balance between pro- and
antiangiogenic molecules. This homeostasis is perfectly controlled
by a tight regulation of the level of angiogenesis inducers and
inhibitors, and any dysregulation is often associated with
pathological settings [21]. Further understanding of the orches-
tration of this balance could help in the development of strategies
to harness the dynamics of blood vessels in human health and
diseases. Identification of miRNAs controlling angiogenesis is thus
a very interesting approach based on their broad-spectrum effects.
Due to its central role in cancer progression and to the close
association between tumor progression and angiogenesis, we
suggest that miR-21 may be involved in angiogenesis. Moreover,
analysis of miRNAs expressed in endothelial cells has revealed that
miR-21 is one of the most highly expressed miRNAs in these cells
[22,23]. In addition, among the different genes reported to be
targets of miR-21, some have been identified as angiogenesis
modulators. The regulator of MAPK activation Sprouty1, whose
antiangiogenic potential has already been demonstrated [24], is
targeted by miR-21 in cardiac fibroblasts [25]. Moreover, a recent
study performed in hepatocellular carcinoma cell lines demon-
strated a direct interaction between miR-21 and the 39UTR of
RhoB, a gene that may be involved in angiogenesis regulation
[26].
In the current study, we first performed in vitro experiments to
test the involvement of miR-21 in angiogenesis. From our data,
miR-21 emerges as a new negative regulator of angiogenesis. Our
results also provide a possible mechanism for miR-21 to inhibit
angiogenesis via RhoB targeting. Moreover, our in vivo study
demonstrates the therapeutic efficacy of miR-21 overexpression in
reducing angiogenesis in a model of pathological choroidal
neovascularization.
Results
Regulation of miR-21 expression by growth factors in
endothelial cells
Several studies have previously demonstrated a high expression
level of miR-21 in endothelial cells [22]. In order to determine a
potential role for miR-21 in angiogenesis, we analyzed the impact
of growth factor treatment on miR-21 expression in human
umbilical vein endothelial cells (HUVECs). miR-21 abundance
was first analyzed in HUVECs cultured in endothelial basal
medium lacking growth factors and serum or in basal medium
supplemented with serum and a cocktail of angiogenic factors.
After 72 hours, we observed a decreased expression of miR-21
when endothelial cells were cultured in basal medium comple-
mented with angiogenic factors and serum (Figure 1A). This
reduced miR-21 expression did not result from a decrease in cell
viability as verified using calcein staining (Figure S1A). In order to
identify which factors are responsible for the reduced expression
level of miR-21, HUVECs were cultured in basal medium
supplemented with the different angiogenic factors added
separately, namely serum, bFGF, VEGF, EGF and hydrocorti-
sone. A lower expression of miR-21 was detected in HUVECs
after the addition of serum and bFGF to the culture medium. No
effects were observed with other growth factors (Figure 1B). The
variation of miR-21 expression level in endothelial cells following
treatment with growth factors suggests that the expression of this
miRNA should be related to endothelial cell quiescence. To test
this hypothesis, miR-21 abundance was measured in HUVECs
cultured in medium containing angiogenic factors supplemented
with the mitogen-activated protein kinase 1/2 (ERK1/2) inhibitor
PD-98059 to induce the quiescence of proliferating HUVECs
[27]. The addition of PD-98059 in the culture medium induced an
increase of miR-21 expression in a dose-dependent manner
(Figure 1C). Analysis of the expression of different miRNAs in
these conditions revealed that the angiomiRs miR-126 and miR-
221 expression levels were also modulated by growth factors
addition to the culture medium while miR-16 expression was not
affected (Figure S1B).
miR-21 overexpression impairs angiogenesis in vitro
In order to investigate miR-21 function in angiogenesis, we
examined the effects of its overexpression in endothelial cell
culture assays. Overexpression of miR-21 in HUVECs was
obtained by transfecting HUVECs with a pre-miR-21 (Ambion)
with a transfection efficiency higher than 90%, as determined
using FITC-siRNA (Integrated DNA Technology) (data not
shown). The level of miR-21 was increased approximately 40-
fold in the presence of the pre-miR-21, as determined by qRT-
PCR (Figure S2).
Endothelial cell proliferation, migration and organization into
tubes are key mechanisms of angiogenesis. In order to investigate
the potential of miR-21 as a regulator of angiogenic processes, we
first evaluated its ability to affect endothelial cell proliferation.
HUVEC proliferation was decreased by 40% upon miR-21
overexpression, as assessed by measuring BrdU incorporation
(Figure 2A). No effect was observed after miR-21 overexpression
on HUVEC apoptosis (data not shown).
The role of miR-21 as a modulator of endothelial cell
organization into tubes was next evaluated. When seeded onto
Matrigel
TM, HUVECs develop into a capillary-like vessel network.
Increasing levels of miR-21 in HUVECs reduced vascular network
formation, as revealed by a similar decrease in tube branching and
total tube length (Figure 2B–D).
In order to investigate whether miR-21 affects endothelial cell
migration, another crucial step of angiogenesis, we performed
migration assays. A modified Boyden chamber was used to
evaluate the ability of HUVECs to migrate to bFGF and serum. A
50% reduction of HUVEC migration was observed in response to
miR-21 overexpression (Figure 2E–F). Similar results were
observed in a wound closure assay, where increasing miR-21
expression reduced endothelial cell capacity to close the scratch
(Figure 2G–H). We also analyzed cell migration in the presence of
the proliferation inhibitor PD-98059 to rule out the potential
implication of cell proliferation in this assay. Under these
conditions, the level of reduced migration (55%) was similar
revealing that miR-21 reduces cell migration independently of its
effect on proliferation (Figure 2H).
To further analyze the role of miR-21 in angiogenesis, we
investigated the effect of silencing endogenously expressed miR-21
in endothelial cells. Inhibition of miR-21 expression in HUVECs
was achieved by transfecting HUVECs with an anti-miR LNA-21
(Exiqon) and compared with cells transfected with a control LNA
miR-21 in Angiogenesis
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increase endothelial cell migration of about 40%, as revealed in a
wound closure assay (Figure 3A–B). We next investigated whether
endogenous miR-21 could alter the ability of HUVECs to form a
vascular network when seeded onto Matrigel
TM (Figure 3C). LNA-
21 transfected HUVECs increased by 2.3 and 1.9 fold the tube
branching number and the total tube length respectively
(Figure 3D–E). Proliferation of LNA-21 transfected HUVECs
showed a trivial effect (Figure 3F). Taken together, these data
indicate that miR-21 affects mainly endothelial cell migration and
tubulogenesis.
miR-21 reduces RhoB expression in endothelial cells
In order to identify putative target genes regulated by miR-21
and involved in the control of angiogenesis, we evaluated targets
computationally predicted by publicly available algorithms
(Targetscan). Using these lists of in silico predicted targets, we
searched for genes that may play a role in angiogenic processes.
Among them we found genes encoding several regulators of
endothelial cell functions and vessel growth, such as the
RhoGTPase RhoB, Sox7, the transforming growth factor beta
receptor II (TGFBRII) and the regulator of ERK activation
Sprouty1 (SPRY1). Regulators of cell migration such as the Rho
guanine nucleotide exchange factor 12 (ARHGEF12), the myosin
phosphatase Rho interacting protein (MPRIP) and vinculin (VCL)
are also listed as putative targets of miR-21. Analysis performed by
qRT-PCR and/or by Western blotting revealed that SOX7,
TGFBRII, ARHGEF12, MPRIP and VCL expression was unaffected
by miR-21 overexpression in HUVECs while SPRY1 was
regulated by miR-21 as revealed by Western blot (Figure S3A-
B). Interestingly, the 39UTR of the RhoB mRNA was found to
contain one predicted binding site for miR-21 conserved between
several species (Figure 4A), which suggest that RhoB might be a
direct target of miR-21. Moreover, RhoB was reported very
recently to be targeted by miR-21 in hepatocellular carcinoma cell
lines. In HUVECs, overexpression of miR-21 significantly
decreased the level of RhoB mRNA expression (Figure 4B). By
contrast, inhibition of miR-21 expression increased RhoB mRNA.
Regulation of endogenous RhoB expression by pre-miR-21 and
LNA-21 was further confirmed at the protein level by Western
blotting (Figures 4C-D). RhoB belongs to a family of small
GTPases composed of three closely related homologs, A, B and C
[28]. In addition, we demonstrated that the regulation of RhoB
mediated by miR-21 was specific for this GTPase, since induction
or repression of miR-21 had no significant effect on the expression
of the other two related RhoGTPases, RhoA and RhoC
(Figure 4C-D).
Since RhoB exists under an inactive GDP-bound state and an
active GTP-bound state, we tested whether the miR-21 expression
level was correlated with the RhoB active state. As measured by a
pull-down assay, the increased miR-21 expression resulted in a
40% decreased level of the active form of RhoB. Moreover, miR-
21 inhibition using LNA anti-miR resulted in a 5 fold increase of
the active RhoB level (Figures 4E–F). Taken together, these results
Figure 1. Regulation of miR-21 expression by growth factors in
endothelial cells. A–C. HUVECs were cultured in basal medium (EBM)
only, basal medium supplemented with a cocktail of angiogenic factors
(EGM) or different amounts of angiogenic factors (serum 5%, bFGF
10 ng/ml, VEGF 50 ng/ml, EGF 20 ng/ml and hydrocortisone 1 ng/ml).
After 72 hours, miR-21 expression was quantified by qRT-PCR. C.
HUVECs were cultured in EBM or in EGM supplemented with increasing
concentrations of PD-98059. miR-21 expression was quantified by qRT-
PCR after 72 hours. A–C. The data were normalized to RNU-44 and
converted using the formula 2
2DDCt (relative expression). Data are
means with the SD. *p,0.05 versus corresponding control; (n=3).
doi:10.1371/journal.pone.0016979.g001
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in endothelial cells.
RhoGTPases are a key determinant in the organization of the
actin cytoskeleton and cell shape. RhoB has been reported to
induce the assembly of actin stress fibers when overexpressed in
endothelial cells [29]. Accordingly, we assessed the ability of miR-
21 to affect actin organization. Although some stress fibers were
still visible, a reduction in the actin stress fiber network in the
center of the cells was observed in cells overexpressing miR-21, as
revealed by a phalloidin staining of F-actin (arrows, Figure 4G).
Moreover, miR-21 overexpressing cells adopt a more round cell-
shape morphology. On the other hand, miR-21 inhibition leads to
an increase in stress fiber formation mainly in the center of the cell
(arrowhead, Figure 4G). On the other hand, miR-21 silenced-cells
adopt a more elongated phenotype (asterisk, Figure 4G). These
results highlight the role of miR-21 in actin stress fiber
organization.
RhoB is a direct target of miR-21 involved in
angiogenesis
To confirm that RhoB is a direct target of miR-21, we
constructed a luciferase reporter vector encoding the complete
39UTR of RhoB (WT RhoB 39UTR) as well as a control vector
containing mismatches in predicted miR-21 binding site (Mut
RhoB 39UTR) (Figure 5A). Cotransfection of the WT RhoB
39UTR plasmid and pre-miR-21 in HEK-293T cells resulted in a
strong decrease in luciferase activity suggesting that RhoB mRNA
is a direct target of miR-21. Importantly, mutations in the
sequence targeted by miR-21 in RhoB 39UTR reduced the
observed down-regulation of luciferase activity by pre-miR-21
validating that this predicted binding site is necessary for miR-21
dependent RhoB expression (Figure 5B).
We then investigated whether the effects of miR-21 expression
in endothelial cells described above (Figures 2-3) could be
mediated by RhoB. If so, inhibition of RhoB expression would
have the same effects on endothelial cell functions as overexpress-
ing miR-21. Knockdown of RhoB expression was achieved
through the use of siRNAs. First, efficacy and specificity of the
siRNA used was verified by Western blotting (Figure 5C). RhoA
and RhoC expression levels were unaffected by the transfection
with the RhoB-siRNA in HUVECs. The ERK1/2 level was
analyzed as an internal control.
We first explored the potential function of RhoB as a modulator
of endothelial cell migration. Inhibition of RhoB expression
resulted in a significant decrease in HUVEC migration, as
revealed by the wound closure assay (Figures 5D–E). Next, the
ability of RhoB to interfere with the organization of endothelial
cells into capillary-like structures was investigated by a tubulogen-
Figure 2. miR-21 overexpression impairs angiogenesis in vitro. HUVECs were transfected with a precursor of miR-21 (Pre-21) or with a
precursor control (Pre-Ctrl) and were assessed for proliferation, tubulogenesis and migration after 48 h. A. Proliferation was determined in transfected
HUVECs treated with bFGF (10 ng/ml) and VEGFa (50 ng/ml) by measuring BrdU incorporation (n=3). B–D. Transfected HUVECs were seeded onto
Matrigel in EGM-2 and then allowed to form capillary-like structures for 16 h. Living cells were labeled with calcein-AM. Representative figures are
shown in (B). Branching number (C) and tube length (D) were quantified with Image J software (n=5–10 pictures/condition; n=3 experiments). E–F.
Transfected HUVECs were allowed to migrate through Boyden chamber inserts for 16 h. The number of cells that migrated to the chamber
containing bFGF and serum was counted and quantified with Image J software. G–H. Migration of transfected HUVECs in a scratch-wound assay 16 h
after treatment with bFGF (10 ng/ml) and VEGFa (50 ng/ml) with or without addition of 10 mM of PD-98059 (n=6–12 measurements/condition; n=3
experiments). Data are means with the SD. *p,0.05 versus corresponding control.
doi:10.1371/journal.pone.0016979.g002
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onto Matrigel. Silencing of RhoB expression in endothelial cells
decreased tube formation, as demonstrated by a 30% reduction in
tube branching (Figures 5F–G) compared to the control siRNA. In
order to determine whether reducing RhoB expression would
affect endothelial cell proliferation, HUVECs were transfected
with a RhoB-siRNA or with a control siRNA. A significant
increased proliferation was observed in cells where RhoB
expression had been silenced, indicating that RhoB-deficient cells
had a higher proliferation rate than control cells (Figure 4H).
Similar results were obtained using another RhoB-siRNA (data
not shown).
To confirm that the reduction in cell migration mediated by
miR-21 is due to RhoB inhibition, we performed miR-21 and
RhoB knockdown, individually or in combination. Inhibition of
miR-21 alone (cotransfection with control siRNA and LNA-21) led
to an increased RhoB expression and to an increased migration
(Figure S4A–B). Conversely, silencing of RhoB alone (cotransfec-
tion with control LNA and RhoB-siRNA) led to a decreased of
RhoB expression and to a reduced migration. Silencing of RhoB
combined with the silencing of miR-21 restored the level of RhoB
expression as well as the migration rate (Figure S4A–B). Altogether
these data confirmed the miR-21-dependent regulation of RhoB
and its implication in the migrating properties of HUVECs.
miR-21 inhibits pathological angiogenesis in a mouse
model of choroidal neovascularization
In order to evaluate the impact of miR-21 in vivo in pathological
angiogenesis, we used a laser-induced murine model of choroidal
neovascularization (CNV), which mimics the age-related macular
degeneration (AMD) pathology [30]. Intravitreal injection of pre-
miR-21 or the control molecule was performed just after laser
burns. Neovascularization in the lesion was assessed seven days
later by epifluorescence microscopy on choroid flat-mounts
following intravenous injection of FITC-dextran (Figure 6A–B).
Isolectin-B4 staining of laser-burned eyes showed that FITC-
Figure 3. Inhibition of miR-21 impairs angiogenesis in vitro. HUVECs were transfected with a LNA-21 or with a LNA control (LNA-Ctrl) and were
assessed for migration, tubulogenesis and proliferation after 48 h. A–B. Migration of transfected HUVECs in a scratch-wound assay 16 h after
treatment with bFGF (10 ng/ml) and VEGFa (50 ng/ml) (n=6–12 measurements/condition; n=3 experiments). C–E. Transfected HUVECs were seeded
onto Matrigel in EGM-2 and then allowed to form capillary-like structures for 16 h. Living cells were labeled with calcein-AM. Representative figures
are shown in (C). Branching numbers (D) and tube length (E) were quantified with Image J software (n=5-10 pictures/condition; n=3 experiments).
Data are means with the SD. *p,0.05. F. Proliferation was determined in transfected HUVECs treated with bFGF (10 ng/ml) and VEGFa (50 ng/ml) by
measuring BrdU incorporation (n=3).
doi:10.1371/journal.pone.0016979.g003
miR-21 in Angiogenesis
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16979Figure 4. miR-21 reduces RhoB expression and activity in endothelial cells. A. Alignment of potential miR-21 binding sites in the 39UTR of
the RhoB mRNA of different species. B. HUVECs were transfected with a precursor of miR-21 (Pre-miR-21) or with a precursor control (Pre-miR-Ctrl)
and with a LNA-21 or with a LNA control (LNA Ctrl). The RhoB mRNA level was analyzed after 48 h by qRT-PCR. C–D. Total protein was extracted from
HUVECs 48 h post transfection and RhoA, RhoB and RhoC protein levels were measured by Western blotting. ERK1/2 level was analyzed as an internal
control. D. Quantification of (C). Quantification was performed using ImageJ software. E–F. Measurement of GTPase activity of RhoB. E. Transfected
HUVECs were processed for pull-down assays and Western blot analysis with specific antibody to RhoB. F. Quantification of (E). Quantification was
performed using ImageJ software. G. Transfected HUVECs were seeded onto gelatin-coated slides and analyzed for fluorescence labeling by
phalloidin-FITC (green). Nuclei were visualized by DAPI staining (blue). White arrows show areas with less actin stress fibers. Asterisks represent some
elongated HUVECs. Arrowhead indicates stress fibers in the center of the cell. Pictures are representative of three independent experiments. Data are
means with the SD. *p,0.05 versus corresponding control; (n=3).
doi:10.1371/journal.pone.0016979.g004
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C). Quantification of the FITC-perfused area revealed a marked
reduction in blood vessel density in animals treated with pre-miR-
21 (Figure 6C). These results indicate the therapeutic efficacy of
miR-21 induction in pathological angiogenesis settings.
Discussion
Several pathologies are associated with excessive angiogenesis
such as cancer, macular degeneration and diabetic retinopathy.
To date, few angiogenic inhibitors have been used in therapy and
these have failed to produce an enduring clinical response in most
patients. Their low efficacy is notably due to the appearance of
resistance mechanisms, as these inhibitors are specific for a single
angiogenic receptor [31,32]. Hence, the ability of one miRNA to
target multiple mRNAs renders them very attractive. Manipulat-
ing angiomiRs in settings of pathological vascularization thus
represents a new therapeutic approach. To date, only few
miRNAs have been found to be involved in angiogenesis
regulation [17].
Figure 5. RhoB-silencing alters endothelial cell migration, proliferation and tubulogenesis. A. Predicted miR-21 binding site within the
RhoB 39UTR. B. The wild-type (WT RhoB 39UTR) or mutated (Mut RhoB 39UTR) reporter plasmid was cotransfected into HEK293T cells with a precursor
of miR-21 (Pre-21) or with a precursor control (Pre-Ctrl). Luciferase activities were quantified 48 h after transfection as described in the materials and
methods section (Luciferase reporter assay and cloning). Renilla luciferase activity was normalized by Firefly luciferase activity. C. HUVECs were
transfected with non-silencing siRNA (siRNA-Ctrl) or with RhoB siRNA and the RhoB protein level was measured after 48 h by Western blotting. The
ERK1/2 level was also measured as an internal control. D–H. HUVECs were transfected as described above and were assessed for migration,
tubulogenesis and proliferation after 48 h. D–E. Migration of transfected HUVECs in a scratch-wound assay 16 h after treatment with bFGF (10 ng/ml)
and VEGFa (50 ng/ml) (n=6–12 measurements/condition; n=3 experiments). F–G. Transfected HUVECs were seeded onto Matrigel in EGM-2 and
then allowed to form capillary-like structures for 16 h. Living cells were labeled with calcein-AM. Representative figures are shown in (F). Branching
numbers (G) were quantified with Image J software (n=5–10 pictures/condition; n=3 experiments). H. Proliferation was assayed in transfected
HUVEC treated with bFGF (10 ng/ml) and VEGFa (50 ng/ml) by measuring BrdU incorporation (n=3). Data are means with the SD. *p,0.05 versus
corresponding control.
doi:10.1371/journal.pone.0016979.g005
miR-21 in Angiogenesis
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which negatively regulates angiogenesis. Using different in vitro
angiogenic assays, we demonstrated that miR-21 overexpression
affects endothelial cell proliferation, migration and organization
into tubes. miR-21 was also found to modify actin cytoskeleton
organization. The organization of actin into stress fibers is known
to play an essential role in promoting cell migration [33]. The
decrease in endothelial cell migration observed upon miR-21
induction may thus be due to reduced stress fiber formation.
In line with its function as a negative modulator of angiogenesis,
we monitored a reduced expression of miR-21 upon the addition
of angiogenic factors to the culture medium. Our results showed
that bFGF and serum acted as inhibitors of miR-21 expression, as
treatment with these molecules was found to decrease miR-21
expression. The increased expression of miR-21 in quiescent
HUVECs suggests that miR-21 could be implicated in the
maintenance of the quiescent vascular endothelium. Interestingly,
the well-known angiogenic miRNA miR-126 followed a similar
pattern highlighting the important role of miRNA in vascular
homeostasis control. The results published by Wu ¨rdinger et al.,
who described a 5-fold reduction in miR-21 and miR-126 levels in
human brain microvascular endothelial cells (HBMVECs) cocul-
tured with glioma cells, used to stimulate angiogenesis [34],
supports our results. Investigation of the level of miR-21 and miR-
126 in proliferating versus quiescent blood vessels could further
help to better understand the role of these miRNAs in vessel
homeostasis.
By affecting key steps of endothelium remodeling, modulation of
miR-21 should provide new strategies to control pathological
angiogenesis. Age-related macular degeneration (AMD), a disease
characterized by an excessive choroidal vascularization (CNV), is
the most frequent cause of blindness in western industrialized
countries. In a mouse model of CNV, which mimics what happens
during AMD, we demonstrated that miR-21 overexpression
reduces neovascularization. These findings suggest the potential
use of miR-21 as a therapeutic tool for treating diseases associated
with excessive angiogenesis. Further studies are still needed to
investigate more precisely the relevance of miR-21 therapeutic use
in other angiogenesis-related diseases such as tumor development.
The antiangiogenic role of miR-21 observed in our study may
be surprising regarding its implication in tumor progression.
Indeed, miR-21 is overexpressed in the vast majority of cancers [6]
and its expression seems to favor tumor growth and invasion.
Inhibition of miR-21 expression has been demonstrated to
increase apoptosis in cultured glioblastoma cells [11], to reduce
breast cancer MCF7 cell growth in vitro and to reduce tumor
growth in a xenograft mouse model [35]. In addition, decreased
tumor cell proliferation, migration and invasion have been found
upon miR-21 silencing in hepatocellular cells [36]. Reduction in
miR-21 expression has also been associated with a reduction in
metastasis in breast and colorectal cancer [37,38]. However, in our
experiments, miR-21 expression induced defects in angiogenesis
processes, as demonstrated by a reduction in endothelial cell
tubulogenesis and migration, without any effect on apoptosis (data
not shown). One explanation of these opposing roles of miR-21 in
tumor cells and the endothelium compartment could be that miR-
21 targets different genes in different cell types. Previous studies
have shown that the differential expression or availability of the
targets between different tissues may direct an miRNA to affect
one specific set of targets [39]. For example, opposing effects on
the proliferation of cancer cells and endothelial cells have already
been reported for miR-221/222. Indeed, whereas high expression
of miR-221/222 blocks angiogenesis and proliferation in endo-
thelial cells via c-kit [18], it promotes proliferation in cancer cells
by targeting the cell cycle regulator p27 [40]. These data suggest
that regulation of proliferation by miR-221 and miR-222 is
specific to the cell type. We thus hypothesize that similar processes
occur with miR-21.
In order to elaborate a putative mechanism for miR-21 to
inhibit angiogenesis, we focused on the identification of the targets
of this miRNA. Taken together, our results support a role for the
RhoGTPase RhoB in the negative function of miR-21 in
angiogenesis. Indeed, RhoB expression and activity were found
to be reduced upon miR-21 expression. RhoGTPases are a family
of 20 small G proteins notably regulating actin cytoskeleton, cell
polarity, vesicular trafficking and gene expression [41]. A growing
amount of evidence has also implicated the Rho-proteins as key
regulators of angiogenesis through the modulation of various steps
of this process, including vascular permeability, extracellular
matrix remodeling, migration and proliferation [42]. The three
best-studied members of the Rho family are RhoA, Rac1 and
cdc42. RhoB has essentially been described in tumor cells where it
Figure 6. miR-21 inhibits pathological angiogenesis in a mouse model of choroidal neovascularization. Adult C57BL/6 mice were
subjected to laser-induced Bruch’s membrane rupture in each eye, and then intravitreally injected with pre-miR-21 (Pre-21) or a control molecule
(Pre-Ctrl). Seven days after Bruch’s membrane rupture at 4 locations, the mice were injected with fluorescein-labeled dextran and the eyes were
removed and mounted for microscopic analysis. Representative pictures are shown in (A–B). C. The choroidal neovascularization area at the Bruch’s
membrane rupture sites was quantified with Image J software. Relative choroidal neovascularization is plotted on the graph. Pictures are
representative of three independent experiments. Optical magnification 10x (n$8 eyes/experiment; n=3 experiments). Data are means with the SD.
*p,0.05.
doi:10.1371/journal.pone.0016979.g006
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described its role in endothelial cells. One group reported a
retarded vascular development in the retina of mice deficient in
RhoB [44]. In cultured endothelial cells, RhoB has been associated
with an increased apoptosis and a failure in tube formation upon
RhoB depletion [44]. Bacterial toxins have also been shown to
inhibit endothelial cell migration by inhibiting the three related
RhoGTPases RhoA, RhoB and RhoC [45]. In line with these
data, our knockdown experiments using RhoB specific siRNAs
indicated a decreased migration capacity and a reduced
organization into tubular structures in endothelial cells. These
effects do not result from defects in apoptosis (data not shown).
The reduction in these processes observed upon miR-21 induction
may thus be explained at least partially, by reduced RhoB
expression and activity caused by miR-21.
Interestingly, the RhoB mRNA contains one putative conserved
binding site for miR-21 in the 39UTR, suggesting that RhoB is a
direct target of miR-21. The conservation of this site during the
evolution suggests that this target may be of functional relevance.
Moreover, a very recently published study demonstrated an
interaction between the 39UTR of RhoB and miR-21 in a
hepatocellular carcinoma cell line [26]. All these data strongly
support the fact that, in endothelial cells, miR-21 also represses
RhoB expression by directly targeting its 39UTR.
Both overexpression and silencing of miR-21 indicate that miR-
21 regulates migration and tubulogenesis. Since silencing of
endogenous miR-21 did not confirm the implication of miR-21 in
cell proliferation, we believe that the reduced proliferation
observed in Pre-miR-21 overexpression is physiologically irrele-
vant. Our results with RhoB silencing support this interpretation.
RhoB silencing decreased migration and tubulogenesis. Combined
with the double knockdown experiments, these results strongly
highlight RhoB as a key target of miR-21-mediated angiogenesis.
However, additional target genes are likely to participate to
miR-21 antiangiogenic effects. Among the putative targets, we
selected SOX7, MPRIP, SPRY1, ARHGEF12, TGFBRII and
VCL that might be involved in regulation of angiogenesis. Except
Spry1, whose expression is down-regulated at the protein level, all
other tested genes were unaffected by miR-21. SPRY1 was shown
to inhibit ERK signaling and we recently showed that SPRY1 is a
negative regulator of angiogenesis [24]. SPRY1 role in miR-21
antiangiogenic response is thus conflicting and further investiga-
tions would clarify its implication in miR-21 response.
In summary, the findings of the present study identify miR-21 as
a novel member of the angiomiR family, acting by negatively
regulating key angiogenic processes such as endothelial cell
migration and tubulogenesis. Our research for relevant target
genes for miR-21 leads us to propose a role for RhoB. Moreover,
the significant reduction in angiogenesis observed in an in vivo
mouse model of CNV after miR-21 overexpression presents miR-
21 as a therapeutic tool for treating aberrant angiogenesis.
Materials and Methods
Mice
All animal experiment protocols were approved by the
Institutional Ethics Committee of the University of Lie `ge and in
compliance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research (permit number 674).
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
isolated as previously described [46]. Briefly, umbilical veins were
washed with PBS, filled with trypsin solution (0.05% trypsin
(Difco); 0.2% EDTA; PBS; pH 7.6), clamped, and incubated in a
37uC water bath for 20 minutes. The umbilical vein was washed
with PBS and the eluate was centrifuged to harvest cells. HUVECs
were seeded onto gelatin-coated culture dishes and cultured in
EGM-2 medium (EGM-2 BulletKit medium (CC-3162, Lonza)
supplemented with 5% fetal bovine serum (FBS)). PD-98059
(Calbiochem) was used at 10 mM in functional assay and at 5 to
25 mM for dose response experiment.
Quantitative miRNA expression analysis by Taqman assay
Total RNAs were extracted with the miRNeasy kit (Qiagen).
Taqman methods were used to assess miRNA expression. Briefly,
10 ng RNA was reverse transcribed to cDNA with the Taqman
microRNA Reverse Transcription kit and the Taqman microRNA
assay stem loop primers (Applied Biosystems). Resulting cDNAs
were used for quantitative real-time PCR using Taqman
microRNA assay and Taqman universal PCR master mix reagents
(Applied Biosystems). Thermal cycling was performed on an ABI
Prism 7900 HT Sequence Detection System (Applied Biosystems).
For all reactions, no-template controls were run, and random
RNA preparations were also subjected to sham reverse transcrip-
tion to check for the absence of genomic DNA amplification. The
relative miRNA level was calculated by the 2
2DDCt method [47]
and normalized to RNU-44 (Applied Biosystems).
In vitro modulation of miRNA-21 and RhoB levels
Modulation of the miR-21 level was performed with modified
oligonucleotides provided by Ambion. For overexpression of miR-
21, HUVECs were transfected with 5 mlo f1 0mM pre-miR-21 or
with control pre-miR oligonucleotides. For inhibition of miR-21,
HUVECs were transfected with 15 nM of LNA-21 or control
LNA (Exiqon). For inhibition of RhoB expression, HUVECs were
transfected with a RhoB-siRNA at a final concentration of 20 nM
or with a control siRNA. HUVECs were transfected with siRNA,
LNA or pre-miR molecules with Dharmafect-4 reagent (Dharma-
con Research) according to the manufacturer’s instructions.
Briefly, 1 ml Dharmafect-4 (Dharmacon Research) was mixed
with 299 ml RPMI1640 (Lonza) and incubated for 10 minutes at
room temperature. siRNA, LNA or pre-miR molecules were
mixed with 295 ml RPMI1640 (Lonza) and incubated for 10
minutes at room temperature. siRNA, LNA or pre-miR mix was
added to the Dharmafect-4 mix and incubated for 20 min at room
temperature before pouring into a 25-cm
2 flask. Cells were then
seeded into the flask (7610
5 cells in 1.4 ml EGM-2 medium) and
incubated for 16 h at 37uC. The medium was then replaced with
3 ml EGM-2 medium and the cells incubated at 37uC for 24 h or
more.
Boyden chamber migration assay
HUVECs were transfected as described above with pre-miR
oligonucleotides for 48 h and divided into eight-micrometer 24-
well Boyden chambers (Transwell; Costar Corp) used for cell
migration assays. Both sides of the membrane were coated
overnight with 0.005% gelatin. The lower chamber was filled with
600 ml EBM-2 medium (Lonza) containing 1% BSA, 1% FBS, and
10 ng/ml recombinant bFGF (Promega Corp). Transfected
HUVECs were placed in 300 ml of 0.1% BSA/EBM-2 in the
upper chamber and allowed to migrate for 16 h at 37uC. After
fixation, cells stained with 4% Giemsa were counted on the lower
side of the membrane. Cell counting was performed with an
ImageJ (http://rsbweb.nih.gov/ij/) macro relying on color thresh-
olding in the RGB color space, followed by connected component
labeling with the ‘‘Analyze Particles’’ function using size and
circularity criteria. The same set of parameters was used for all
miR-21 in Angiogenesis
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checked by visual examination.
Scratch wound migration assay
HUVECs transfected with siRNA, LNA or pre-miR as
described above were trypsinized 48 h post-transfection. Following
this, 5610
4 cells were seeded into a 48-well plate in 350 ml EGM-2
medium (Lonza) and incubated for 24 h to reach confluence.
Using a tip, a wound was made in the monolayer (at time 0). The
cells were then washed with PBS and incubated with EBM-2
medium containing 10 ng/ml recombinant bFGF (Promega
Corp.) and 50 ng/ml recombinant VEGFa (RELIATech GmbH)
for 16 h. The distance between the two sides of the wound was
measured with a graduated ocular lens coupled with an Olympus
CKX41 microscope (Olympus). The distance between the two
sides of the wound after 16 h of migration was substracted from
the distance at time 0 and represented on a graph.
Capillary network formation on a Matrigel matrix
The ability of RhoB siRNA-, LNA-21- or pre-miR-21-
transfected HUVECs to form capillary networks was evaluated
in a Matrigel
TM angiogenesis assay. Briefly, 8750 HUVECs
transfected as described above were plated in a 96-well plate pre-
coated with 35 ml Matrigel per well (BD Biosciences) 48 h post-
transfection. The cells were incubated in EGM-2 medium for 16 h
(Lonza). In order to visualize vessels under a fluorescence
microscope, the cells were incubated with calcein-AM (2 mM) for
20 min. Pictures were taken with an Olympus fluorescence
microscope (Olympus). Quantitative analysis of network structure
was performed with ImageJ software (http://rsbweb.nih.gov/ij/)
by counting the number of intersections in the network and
measuring the total length of the structures.
Analysis of cell proliferation
HUVECs were transfected as described above with siRNA,
LNA or pre-miR oligonucleotides for 48 h. Following this,
transfected cells were plated in 96-well culture plates at a density
of 1500 cells per well in EGM-2 medium (Lonza) and allowed to
adhere for 16 h. The medium was washed with PBS and replaced
with EBM-2 medium supplemented with recombinant bFGF
(10 ng/ml) (Promega Corp.) and recombinant VEGFa (50 ng/ml)
(RELIATech GmbH). 16 hours later, BrdU was added and the
culture was incubated for 8 hours. BrdU incorporation was
measured with the Cell Proliferation ELISA BrdU (chemilumi-
nescence) kit (Roche Applied Sciences) according to the manu-
facturer’s protocol.
qRT-PCR analysis of gene expression
RNAs were extracted with the miRNeasy kit (Qiagen) according
to the manufacturer’s protocol. cDNA synthesis was performed
with 1 mg total RNA and the iScript cDNA Synthesis Kit (Biorad)
according to the manufacturer’s instructions. Resulting cDNAs
were used for quantitative real-time PCR using the SYBR green
method (Roche Applied Sciences). Thermal cycling was performed
on an ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems). For all reactions, no-template controls were run, and
random RNA preparations were also subjected to sham reverse
transcription to check for the absence of genomic DNA
amplification. The relative transcript level of each gene was
obtained by the 2
2DDCt method [47] and normalized with respect
to the housekeeping gene cyclophilin a (PPIA) or glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). Primers were designed
with the Primer Express software (Applied Biosystems) and
selected so as to span exon-exon junctions to avoid detection of
genomic DNA (see Table S1 – List of primers used in quantitative
RT-PCR experiments).
Western blotting
Cytoplasmic cell lysate was resolved by SDS-PAGE and
transferred to a polyvinylidene fluoride membrane (Millipore
Corp.). Blots were blocked for 1 h at room temperature with 8%
milk in Tris-buffered saline with 0.1% Tween 20 and probed
overnight at 4uC with anti-RhoB, RhoA or RhoC primary
antibody (RhoA sc-418; RhoB sc-180, RhoC sc-26480 Santa Cruz
Biotechnology) (or for 1 h at room temperature for anti-ERK1,2
M-5670, VCL V-9131, Sigma; Sox7 sc-134024, Santa Cruz
Biotechnology; MPRIP ab56164, Abcam and 2 h at 37uC for
SPRY1 sc-380048 Santa Cruz Biotechnology). After three washes
with Tris-buffered saline containing 0.1% Tween 20, antigen-
antibody complexes were detected with peroxidase-conjugated
secondary antibody and a fluoro-chemiluminescent system (GE
Healthcare).
Cytoskeleton labeling
HUVECs were transfected with pre-miR or LNA molecules as
described above. 24 h later, cells were harvested and 3610
4 cells
were seeded onto glass coverslips pre-coated with gelatin (2 g/l), in
24-well plates containing 500 ml of EGM-2 medium (Lonza,
Verviers, Belgium). 24 h later, medium was removed and cells
were washed twice. For fibrillar actin labeling, HUVECs were
fixed with 1% paraformaldehyde in PBS for 30 min and
permeabilized with 0.2% Triton X-100 in PBS for 5 min. The
samples were blocked with 0.2% bovine serum albumin in PBS for
30 min and incubated with 5 mg/ml of phalloidin-FITC and with
2 mg/ml of 49,6-diamidino-2-phenylindole for 30 min. Stained
cells were washed twice in PBS and mounted using Vectashield
mounting medium (Vector Laboratories, Burlingame, CA).
Pictures were obtained using a Nikon Eclipse 90i epifluorescent
microscope coupled to a digital camera (Nikon Belux, Brussels,
Belgium).
GTPase assay
HUVECs were transfected with pre-miR or LNA molecules, as
previously described, for 48 h. The GTPase assay was carried out
as previously described [48]. Briefly, cells were chilled on ice and
lysed in ice-cold buffer containing 0.5% Triton X-100, 25 mM
Hepes pH 7.3, 150 mM NaCl, 4% glycerol, 5 mM MgCl2,
0.5 mM EGTA, 10 mM NaF, 20 mM b-glycerophosphate, 5 mM
DTT and a tablet of protease inhibitor cocktail (Roche Applied
Sciences). Lysates were centrifuged for 5 min at 14 000 g.
Supernatants were immediately frozen in liquid nitrogen and
stored at 280uC. An aliquot of each supernatant collected before
freezing was denatured in SDS-PAGE lysis buffer to measure the
total RhoGTPase content by Western blotting. For the pull-down
assay, supernatants were incubated for 30 min with 30 mg of GST-
RBD fusion protein containing GST fused to the Rho-binding
region of rhotekin affinity, linked to glutathione-Sepharose beads.
The beads were washed 4 times in lysis buffer and boiled in 60 ml
of SDS-PAGE lysis buffer.
Luciferase reporter assay and cloning
Full length RhoB 39UTR was amplified by PCR using the
following primers: forward CTCGAGACTGCTGCAAGGTGC-
TATGAGG; reverse GCGGCCGCCTCGCCTAGGAGAATA-
TCTCCC; and cloned in the PsiCheck-2 vector (Promega) using
XhoI, HindIII restriction sites. Mutagenesis of the seed sequence
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Kit (Stratagene) following manufacturers’ instructions. For mea-
suring luciferase activity, 175000 HEK293T cells were transfected
in 24-well plate with 30 pmol of Pre-miR-control or Pre-miR-21
oligonucleotides as described above. The day after, wild-type or
mutated RhoB-Psicheck-2 was transfected using JET-PEI (Poly-
plus transfection) according to manufacturers’ instructions and
incubated for 48 h. The activity of Renilla and Firefly Luciferase
was then assessed using the Dual-LuciferaseH Reporter Assay
System (Promega) following manufacturer protocol.
In vivo choroidal neovascularization experiment
The two-month-old C57BL/6 mice (five mice in each group)
used in this study were maintained in a 12 hours light–12 hours
dark cycle and had free access to food and water. All animal
experiments were performed in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. Choroidal neovascularization (CNV) was induced in
mice by laser burns as described previously [49]. Mice were
anesthetized with an ip injectionof Avertin. Both pupilsweredilated
with 1% tropicamide; four burns were delivered (usually at the 3, 6,
9, and 12 o’clock positions around the optic disc) using a green
argon laser (532 nm; 50 mm diameter spot size; 0.05 sec duration;
400 mW). The eyes were locally anesthetized with 4 mg/ml
Oxybuprocaini HCl (Unicaı ¨ne 0.4% - The ´a), with this being
immediately followed by intravitreal injection of 2 ml control pre-
miR or pre-miR-21 at 5 mM. After this, 3 mg/g ofloxacin ointment
(TrafloxalH - Dr. Mann Pharma) was applied to the eye. Seven days
later, the mice were injected (i.v.) with 200 ml fluorescein
isothiocyanate (FITC)-conjugated dextran (Mr: 2610
3, Sigma-
Aldrich) in PBS, pH 7.4 just before exsanguination. Afterward, the
eyes were removed and fixed in 1% paraformaldehyde, pH 7.4 for
1 h at room temperature. The retinas were discarded and the
choroid was prepared in Vectashield medium (Vector Laboratories)
for epifluorescence microscopy (Nikon Belux). Quantification was
carried out by measuring the total vessel fluorescence surface
(ImageJ software http://rsbweb.nih.gov/ij/, NIH) as described in
figure S6A-D. Seven days after choroid lesions appeared at thirty
different locations, total RNA extraction was performed for miRNA
quantification as described above.
Isolectin-B4 staining of fluorescein-labeled eyes
Paraformaldehyde 1% fixed eyes were trypsinised (0,025%) at
37uC during 25 min. Eyes were washed and blocked in milk 1.5%
during 30 min at room temperature and then incubated in PBS
milk 10%, containing IB4-Biotinylated antibody for 2 h at 37uC
(Griffonia Simplicifolia isolectin-B4 biotinylated antibody, I-
21414, Molecular Probes). Eyes were washed with PBS and
incubated with Streptavidin-Cy3 antibody 30 min at room
temperature, washed in PBS and mounted with Vectashield
(Vector Laboratories). Pictures were obtained using an AH3-
RFCA epifluorescence microscope coupled to a digital camera
(Olympus).
Quantifications and statistical analysis
Analyses for statistical significance (Unpaired t-test) were carried
out with Prism 4.0 software (GraphPad Software, San Diego, CA,
USA). Statistical significance was set at P,0.05. All data are
expressed as means 6 SD.
Supporting Information
Figure S1 HUVEC viability in basal medium and
miRNA expression in medium containing or not growth
factors. A. HUVECs were cultured in basal medium (EBM) and
were analyzed for fluorescence by calcein staining (2 mM) after 72
hours. B. HUVECs were cultured in EBM, in EGM or in EGM
supplemented with 10 mM of PD-98059 for 72 hours. Expression
of miR-21, miR-126, miR-16 and miR-221 was quantified by
qRT-PCR. The data were normalized to RNU-44 and converted
using the formula 2
–DDCt (relative expression). Data are means
with the SD. *p,0.05 versus corresponding control; (n=3).
(TIF)
Figure S2 miR-21 expression following precursor mol-
ecule transfections. HUVECs were transfected with a
precursor of miR-21 (Pre-21) or with a precursor control (Pre-
Ctrl) for 72 h. miR-21 expression was quantified by qRT-PCR.
The data were normalized with respect to RNU-44 and converted
using the formula 2
–DDCt (relative expression). Data are means
with the SD. *p,0.05 versus corresponding control; (n=3).
(TIF)
Figure S3 Regulation of SOX7, TGFBRII, ARHGEF12,
MPRIP, VCL and SPRY1 expression by miR-21. A.
HUVECs were transfected with a precursor of miR-21 (Pre-21)
or with a precursor control (Pre-Ctrl) for 48 h. SOX7, SPRY1,
TGFBRII, ARHGEF12, MPRIP and VCL expression was analyzed
by qRT-PCR. The data were normalized with respect to PPIA
and converted using the formula 2
–DDCt (relative expression). Data
are means with the SD. *p,0.05 versus corresponding control;
(n=3). B. Total protein was extracted from HUVECs 48 h post
transfection and MPRIP, SOX7, SPRY1 and VCL protein levels
were measured by Western blotting. b-tubulin was analyzed as an
internal control (representative of 3 independent experiments).
(TIF)
Figure S4 Double knockdown of miR-21 and RhoB
restore RhoB expression and HUVECs migration.
HUVECs were transfected with a LNA-21 or with a LNA control
(LNA-Ctrl). Twenty-four hours later, HUVECs were transfected
again with non-silencing siRNA (Control-siRNA) or with RhoB
siRNA (RhoB siRNA). A. The RhoB mRNA level was analyzed 24
h after transfection with siRNAs by qRT-PCR. The data were
normalized to GAPDH and converted using the formula 2
–DDCt
(relative expression). B. Transfected HUVECs were assessed 48 h
later for migration in a scratch-wound assay 16 h after treatment
with bFGF (10 ng/ml) and VEGFa (50 ng/ml) (n=6-12
measurements/condition; n=3 experiments). Data are means
with the SD. *p,0.05 versus corresponding control.
(TIF)
Figure S5 Staining of the choroidal neovascularized
blood vessels. Adult C57BL/6 mice were subjected to laser-
induced Bruch’s membrane rupture in each eye, and then
intravitreally injected with pre-miR-21 or a control molecule.
Seven days after Bruch’s membrane rupture at 4 locations, the
mice were injected with fluorescein-labeled dextran and the eyes
were removed and mounted for microscopic analysis. A.
Representative picture. B. Isolectin-B4 staining of fluorescein-
labeled eyes. C. Overlay of (A-B). Arrows indicate fluorescein- and
isolectin-B4- labeled blood vessel. Arrowheads indicate isolectin-
B4-labeled blood vessel not perfused with fluorescein.
(TIF)
Figure S6 Choroidal neovascularization quantification.
Adult C57BL/6 mice were subjected to laser-induced Bruch’s
membrane rupture in each eye, and then intravitreally injected
with pre-miR-21 or a control molecule. Seven days after Bruch’s
miR-21 in Angiogenesis
PLoS ONE | www.plosone.org 11 February 2011 | Volume 6 | Issue 2 | e16979membrane rupture at 4 locations, the mice were injected with
fluorescein-labeled dextran and the eyes were removed and
mounted for microscopic analysis. A-D. Fluorescein-labeled blood
vessels quantification. A. Original Red-Green-Blue color picture.
B. Selection of the blood vessels area using ImageJ erases the
background from the original picture. C. Extraction of the green
component. D. Quantification using ImageJ of the pixels (shown
in red in the picture) after application of the threshold to mainly
select blood vessels structures.
(TIF)
Table S1 List of primers used in quantitative RT-PCR.
Sequences of all primers used in qRT-PCR experiments are listed.
(DOC)
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